The 2026 version of the Global Initiative for Chronic Obstructive Lung Disease (GOLD) strategy report has been published. Key ...

Discover how cell-based therapy is emerging as a promising treatment option for COPD patients. Learn about its benefits, ...

The findings provide further support of recommendations in the clinical guidelines to favor one therapy over the other. Patients with chronic obstructive pulmonary disease (COPD) being treated with ...

Glenmark Pharmaceuticals added 1.75% after the company announced launch of Nebzmart GFB Smartules and Glenmark Airz FB Smartules, the world's first nebulized, fixed-dose triple therapy for Chronic ...

Triple therapy for COPD, vs ICS/LABA therapy, was independently associated with ischemic heart disease, heart failure, arrhythmia, and atrial fibrillation/flutter. Cardiovascular events in patients ...

A new study from University Hospitals Connor Whole Health found that it was feasible to conduct a hybrid music therapy intervention for patients with heart failure and patients with chronic ...

Please provide your email address to receive an email when new articles are posted on . More time between an exacerbation and start of COPD triple therapy increased rate of future exacerbations.

Among older adults with chronic obstructive pulmonary disease (COPD), particularly those with asthma, newly prescribed long-acting beta-agonists (LABAs) and inhaled corticosteroid combination therapy, ...

Patients with chronic obstructive pulmonary disease (COPD) receiving triple therapy face an increased cardiovascular risk, according to a study published in the International Journal of Chronic ...

The company has launched Nebzmart® GFB Smartules® and Glenmark Airz® FB Smartules®, world's first nebulised, fixed-dose ...